Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

Similar articles for PubMed (Select 18590744)

1.

Involvement of the second extracellular loop and transmembrane residues of CCR5 in inhibitor binding and HIV-1 fusion: insights into the mechanism of allosteric inhibition.

Maeda K, Das D, Yin PD, Tsuchiya K, Ogata-Aoki H, Nakata H, Norman RB, Hackney LA, Takaoka Y, Mitsuya H.

J Mol Biol. 2008 Sep 12;381(4):956-74. doi: 10.1016/j.jmb.2008.06.041. Epub 2008 Jun 20.

2.
3.

Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function.

Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, Berg E, Liu G, Guy HR, Durell SR, Parmentier M, Chang CN, Price K, Tsang M, Doms RW.

J Biol Chem. 1999 Apr 2;274(14):9617-26.

4.

A critical site in the core of the CCR5 chemokine receptor required for binding and infectivity of human immunodeficiency virus type 1.

Siciliano SJ, Kuhmann SE, Weng Y, Madani N, Springer MS, Lineberger JE, Danzeisen R, Miller MD, Kavanaugh MP, DeMartino JA, Kabat D.

J Biol Chem. 1999 Jan 22;274(4):1905-13.

5.

Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1.

Dogo-Isonagie C, Lam S, Gustchina E, Acharya P, Yang Y, Shahzad-ul-Hussan S, Clore GM, Kwong PD, Bewley CA.

J Biol Chem. 2012 Apr 27;287(18):15076-86. doi: 10.1074/jbc.M111.332361. Epub 2012 Mar 8.

6.

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.

Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP, Moore JP.

Proc Natl Acad Sci U S A. 2000 May 9;97(10):5639-44.

7.

Highly conserved beta16/beta17 beta-hairpin structure in human immunodeficiency virus type 1 YU2 gp120 is critical for CCR5 binding.

Mechulam A, Cerutti M, Pugnière M, Missé D, Gajardo J, Roquet F, Robinson J, Veas F.

J Mol Med (Berl). 2005 Jul;83(7):542-52. Epub 2005 May 19.

PMID:
15905975
8.
9.

Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5.

Olson WC, Rabut GE, Nagashima KA, Tran DN, Anselma DJ, Monard SP, Segal JP, Thompson DA, Kajumo F, Guo Y, Moore JP, Maddon PJ, Dragic T.

J Virol. 1999 May;73(5):4145-55.

11.

HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less-efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism.

Roche M, Jakobsen MR, Sterjovski J, Ellett A, Posta F, Lee B, Jubb B, Westby M, Lewin SR, Ramsland PA, Churchill MJ, Gorry PR.

J Virol. 2011 May;85(9):4330-42. doi: 10.1128/JVI.00106-11. Epub 2011 Feb 23.

12.

Theoretical studies on the interactions and interferences of HIV-1 glycoprotein gp120 and its coreceptor CCR5.

Da LT, Wu YD.

J Chem Inf Model. 2011 Feb 28;51(2):359-69. doi: 10.1021/ci1003448. Epub 2011 Feb 2.

PMID:
21284403
13.

Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.

Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Shibayama S, Sagawa K, Fukushima D, Moravek J, Koyanagi Y, Mitsuya H.

J Virol. 2004 Aug;78(16):8654-62.

15.

Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR, McCombie S, Baroudy B, Moore JP, Sakmar TP, Dragic T.

J Virol. 2003 May;77(9):5201-8.

16.

Multiple charged and aromatic residues in CCR5 amino-terminal domain are involved in high affinity binding of both chemokines and HIV-1 Env protein.

Blanpain C, Doranz BJ, Vakili J, Rucker J, Govaerts C, Baik SS, Lorthioir O, Migeotte I, Libert F, Baleux F, Vassart G, Doms RW, Parmentier M.

J Biol Chem. 1999 Dec 3;274(49):34719-27.

17.

Allosteric model of maraviroc binding to CC chemokine receptor 5 (CCR5).

Garcia-Perez J, Rueda P, Alcami J, Rognan D, Arenzana-Seisdedos F, Lagane B, Kellenberger E.

J Biol Chem. 2011 Sep 23;286(38):33409-21. doi: 10.1074/jbc.M111.279596. Epub 2011 Jul 20.

18.

Structural and molecular interactions of CCR5 inhibitors with CCR5.

Maeda K, Das D, Ogata-Aoki H, Nakata H, Miyakawa T, Tojo Y, Norman R, Takaoka Y, Ding J, Arnold GF, Arnold E, Mitsuya H.

J Biol Chem. 2006 May 5;281(18):12688-98. Epub 2006 Feb 13.

19.

Peptide ligands selected with CD4-induced epitopes on native dualtropic HIV-1 envelope proteins mimic extracellular coreceptor domains and bind to HIV-1 gp120 independently of coreceptor usage.

Dervillez X, Klaukien V, Dürr R, Koch J, Kreutz A, Haarmann T, Stoll M, Lee D, Carlomagno T, Schnierle B, Möbius K, Königs C, Griesinger C, Dietrich U.

J Virol. 2010 Oct;84(19):10131-8. doi: 10.1128/JVI.00165-10. Epub 2010 Jul 21.

20.

Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.

Kondru R, Zhang J, Ji C, Mirzadegan T, Rotstein D, Sankuratri S, Dioszegi M.

Mol Pharmacol. 2008 Mar;73(3):789-800. Epub 2007 Dec 20.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk